ASD
MCID: ATS007
MIFTS: 68

Autism Spectrum Disorder (ASD)

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Autism Spectrum Disorder

MalaCards integrated aliases for Autism Spectrum Disorder:

Name: Autism Spectrum Disorder 12 54 26 30 6 44 45 15 17
Asd 54 26
Pervasive Developmental Disorder 26
Pervasive Development Disorder 74
Autism Spectrum Disorders 74
Autistic Continuum 26
Autistic Behavior 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0060041
MeSH 45 D000067877

Summaries for Autism Spectrum Disorder

MedlinePlus : 44 Autism spectrum disorder (ASD) is a neurological and developmental disorder that begins early in childhood and lasts throughout a person's life. It affects how a person acts and interacts with others, communicates, and learns. It includes what used to be known as Asperger syndrome and pervasive developmental disorders. It is called a "spectrum" disorder because people with ASD can have a range of symptoms. People with ASD might have problems talking with you, or they might not look you in the eye when you talk to them. They may also have restricted interests and repetitive behaviors. They may spend a lot of time putting things in order, or they may say the same sentence again and again. They may often seem to be in their "own world." At well-child checkups, the health care provider should check your child's development. If there are signs of ASD, your child will have a comprehensive evaluation. It may include a team of specialists, doing various tests and evaluations to make a diagnosis. The causes of ASD are not known. Research suggests that both genes and environment play important roles. There is currently no one standard treatment for ASD. There are many ways to increase your child's ability to grow and learn new skills. Starting them early can lead to better results. Treatments include behavior and communication therapies, skills training, and medicines to control symptoms. NIH: National Institute of Child Health and Human Development

MalaCards based summary : Autism Spectrum Disorder, also known as asd, is related to autism and pervasive developmental disorder, and has symptoms including widespread abnormalities of social interactions, severely restricted interests and highly repetitive behavior. An important gene associated with Autism Spectrum Disorder is SHANK2 (SH3 And Multiple Ankyrin Repeat Domains 2), and among its related pathways/superpathways are MicroRNAs in cancer and Brain-Derived Neurotrophic Factor (BDNF) signaling pathway. The drugs Oxytocin and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye.

Disease Ontology : 12 A pervasive developmental disorder that is a spectrum of psychological conditions. The disease has symptom widespread abnormalities of social interactions and communication, has symptom severely restricted interests and has symptom highly repetitive behavior.

Genetics Home Reference : 26 Autism spectrum disorder (ASD) is a condition that appears very early in childhood development, varies in severity, and is characterized by impaired social skills, communication problems, and repetitive behaviors. These difficulties can interfere with affected individuals' ability to function in social, academic, and employment settings. People with ASD also have an increased risk of psychiatric problems such as anxiety, depression, obsessive-compulsive disorder, and eating disorders.

NIH Rare Diseases : 54 Autism spectrum disorder (ASD) is a condition that affects the development of social and communication skills. It includes features of four conditions which were once thought to be separate syndromes - autistic disorder, Asperger syndrome, childhood disintegrative disorder, and pervasive developmental disorder. Signs and symptoms often become apparent in the first 2-3 years of life and vary significantly from person to person. Common symptoms shared by people with ASD include restrictive and repetitive behaviors, social impairment and communication difficulties. The underlying cause of ASD is generally unknown and it is likely that a variety of factors contribute to the development of the condition. ASD appears to run in some families, suggesting that genetics may play a role in some cases. Although there is no cure for ASD, treatment is available that significantly improves the long-term outlook for affected people. Treatment often includes a combination of techniques such as medications, occupational therapy, speech therapy and physical therapy.

NINDS : 55 Autistic disorder (sometimes called autism or classical ASD) is the most common condition in a group of developmental disorders known as the autism spectrum disorders (ASDs).   Autistic children have difficulties with social interaction, display problems with verbal and nonverbal communication, and exhibit repetitive behaviors or narrow, obsessive interests. These behaviors can range in impact from mild to disabling. Autism varies widely in its severity and symptoms and may go unrecognized, especially in mildly affected children or when more debilitating handicaps mask it. Scientists aren’t certain what causes autism, but it’s likely that both genetics and environment play a role.   Autism spectrum disorder is diagnosed based on symptoms, signs, and other testing according to the Diagnostic and Statistical Manual V, a guide created by the American Psychiatric Association to diagnose mental disorders. Children should be screened for developmental delays during periodic checkups and specifically for autism at 18- and 24-month well child visits.

Related Diseases for Autism Spectrum Disorder

Diseases in the Autism family:

Autism 8 Autism 3
Autism 6 Autism 7
Autism 11 Autism 12
Autism 13 Autism 9
Autism 10 Autism 15
Autism 16 Autism 17
Autism 18 Autism 19
Autism Spectrum Disorder

Diseases related to Autism Spectrum Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 404)
# Related Disease Score Top Affiliating Genes
1 autism 34.0 EHMT1 PTCHD1 RPL10 SHANK2 SHANK3 TSC2
2 pervasive developmental disorder 33.8 PTCHD1 RPL10 SHANK2 SHANK3 TSC2
3 schizophrenia 31.0 DISC2 EHMT1 MIR106B MIR15A MIR15B SHANK3
4 adnp-related intellectual disability and autism spectrum disorder 12.4
5 patent foramen ovale 12.1
6 adnp syndrome 12.0
7 arthrogryposis, mental retardation, and seizures 11.8
8 helsmoortel-van der aa syndrome 11.8
9 asperger syndrome 11.7
10 atrial septal defect 1 11.6
11 anterior segment dysgenesis 11.6
12 atrial septal defect ostium primum 11.6
13 timothy syndrome 11.5
14 chromosome 15q13.3 deletion syndrome 11.5
15 childhood disintegrative disease 11.5
16 fragile x syndrome 11.5
17 atrial heart septal defect 11.4
18 specific language impairment 11.4
19 rett syndrome 11.4
20 landau-kleffner syndrome 11.4
21 speech and communication disorders 11.4
22 atypical autism 11.4
23 16p11.2 duplication 11.4
24 interatrial communication 11.3
25 mental retardation, autosomal recessive 38 11.3
26 mental retardation, autosomal dominant 26 11.3
27 chromosome 15q11.2 deletion syndrome 11.3
28 neurodevelopmental disorder with or without anomalies of the brain, eye, or heart 11.3
29 atrial septal defect 7 with or without atrioventricular conduction defects 11.2
30 autism x-linked 4 11.2
31 epilepsy, familial focal, with variable foci 1 11.2
32 specific language impairment 5 11.2
33 schaaf-yang syndrome 11.2
34 white-sutton syndrome 11.2
35 syngap1-related intellectual disability 11.2
36 atrial septal defect coronary sinus 11.1
37 atrial septal defect sinus venosus 11.1
38 familial pulmonary arterial hypertension leucopenia and atrial septal defect 11.1
39 corpus callosum, agenesis of 11.0
40 autism x-linked 1 11.0
41 autism x-linked 2 11.0
42 autism x-linked 3 11.0
43 autism x-linked 5 11.0
44 autism x-linked 6 11.0
45 chromosome 2q37 deletion syndrome 11.0
46 potocki-shaffer syndrome 11.0
47 athabaskan brainstem dysgenesis syndrome 11.0
48 macrocephaly/autism syndrome 11.0
49 intellectual developmental disorder with autism and speech delay 11.0
50 autism 8 11.0

Graphical network of the top 20 diseases related to Autism Spectrum Disorder:



Diseases related to Autism Spectrum Disorder

Symptoms & Phenotypes for Autism Spectrum Disorder

Symptoms:

12
  • widespread abnormalities of social interactions
  • severely restricted interests
  • highly repetitive behavior

UMLS symptoms related to Autism Spectrum Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances

Drugs & Therapeutics for Autism Spectrum Disorder

Drugs for Autism Spectrum Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-56-6 439302 53477758
2
Acetylcholine Approved, Investigational Phase 4,Phase 1,Not Applicable 51-84-3 187
3
Donepezil Approved Phase 4,Phase 2,Phase 1 120014-06-4 3152
4
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
5
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
6
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 113-45-1 4158
7
Buspirone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 36505-84-7 2477
8
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 19982-08-2 4054
9
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Not Applicable 616-91-1 12035
10
Guanfacine Approved, Investigational Phase 4,Not Applicable 29110-47-2 3519
11
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
12
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
13
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
14
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
15
Olanzapine Approved, Investigational Phase 4,Phase 2,Phase 3 132539-06-1 4585
16
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
17
Minocycline Approved, Investigational Phase 4,Phase 1 10118-90-8 5281021
18
Valproic Acid Approved, Investigational Phase 4,Phase 2 99-66-1 3121
19
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
20
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
21
Choline Approved, Nutraceutical Phase 4 62-49-7 305
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59-30-3 6037
23
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 73-31-4 896
24
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
25 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Oxytocics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Lipid Regulating Agents Phase 4,Not Applicable
28 Vasodilator Agents Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
29 Nootropic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Hypolipidemic Agents Phase 4,Not Applicable
34 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
36 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Dopamine D2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
40 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Dopamine agonists Phase 4,Phase 3,Phase 2
42 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Serotonin Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Serotonin 5-HT1 Receptor Agonists Phase 4,Phase 3,Phase 2
48 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Rho(D) Immune Globulin Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 934)
# Name Status NCT ID Phase Drugs
1 Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders Unknown status NCT02940574 Phase 4 Syntocinon (Oxytocin)
2 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
3 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4 Aripiprazole
4 An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Unknown status NCT02199925 Phase 4 Gammaplex 5%
5 Improving Driving in Young People With Autism Spectrum Disorders Recruiting NCT03538431 Phase 4 Buspirone
6 A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders Completed NCT01333865 Phase 4 Memantine
7 FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders Completed NCT01028820 Phase 4 Aripiprazole
8 Omega-3 Fatty Acids in Autism Spectrum Disorders Completed NCT01695200 Phase 4
9 Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD) Using Telepsychiatry of Complementary and Alternative Treatments Not yet recruiting NCT03757585 Phase 4 Open-label Treatment with Omega-3 Fatty Acids + Inositol;Open-label Treatment with N-Acetyl Cysteine
10 Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders Terminated NCT01033565 Phase 4 Natrol
11 Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD Completed NCT02096952 Phase 4 Methylphenidate extended-release liquid formulation
12 Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder Completed NCT01238575 Phase 4 extended-release guanfacine
13 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder Completed NCT00380692 Phase 4 Atomoxetine;Placebo
14 Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Recruiting NCT03337646 Phase 4 Lisdexamfetamine Dimesylate
15 Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes Enrolling by invitation NCT03333629 Phase 4
16 Atomoxetine, Placebo and Parent Management Training in Autism Completed NCT00844753 Phase 4 atomoxetine;Placebo
17 Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Completed NCT02255565 Phase 4 Very Low Dose Quillivant XR;Low Dose Quillivant XR;Moderate Dose Quillivant XR
18 Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism Completed NCT02235467 Phase 4
19 Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism Completed NCT01337700 Phase 4 Milnacipran;Placebo
20 Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Completed NCT01683565 Phase 4 LCPUFA oil supplement
21 A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD Completed NCT00485849 Phase 4 Atomoxetine Hydrochloride
22 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Completed NCT01339858 Phase 4 N-Acetyl Cysteine
23 An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. Completed NCT00391261 Phase 4 Metformin
24 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4 risperidone;olanzapine;aripiprazole
25 Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART) Completed NCT01333072 Phase 4 Aripiprazole;Risperidone
26 Minocycline to Treat Childhood Regressive Autism Completed NCT00409747 Phase 4 Minocycline
27 Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study Completed NCT00352196 Phase 4 Risperidone
28 Divalproex Sodium ER in Adult Autism Completed NCT00211796 Phase 4 Divalproex Sodium ER
29 Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder Completed NCT01227668 Phase 4 Aripiprazole;Placebo
30 A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder Completed NCT00576732 Phase 4 Placebo;Risperidone high dose;Risperidone low dose
31 A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants Active, not recruiting NCT00756600 Phase 4 Regional Anesthesia;General Anesthesia
32 A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children Completed NCT01050582 Phase 4 Risperidone;Other atypical antipsychotic drugs
33 Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders Unknown status NCT02757066 Phase 2, Phase 3 NPC-15 Granules Lower Dose;NPC-15 Granules Higher Dose;NPC-15 Placebo Granule
34 Group Psychoeducational Program for Mothers of Children With High Functional Pervasive Developmental Disorders Unknown status NCT01243905 Phase 2, Phase 3
35 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
36 Oxytocin in Adolescents With Autism Spectrum Disorders Suspended NCT02007447 Phase 2, Phase 3 OCYTOCINA - SPRAY NASAL
37 Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder Completed NCT01972074 Phase 3 Memantine;Placebo
38 Cortical Metrics in Intervention Trials With Autism Spectrum Disorders Withdrawn NCT02212275 Phase 2, Phase 3 Dextromethophan
39 A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension Recruiting NCT03504917 Phase 3 Balovaptan;Placebo
40 Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders Completed NCT02081027 Phase 2, Phase 3 Riluzole;placebo
41 Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. Recruiting NCT03715153 Phase 3 BUMETANIDE/S95008;PLACEBO
42 A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder Active, not recruiting NCT02985749 Phase 3 Intranasal Oxytocin
43 Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders Terminated NCT01706523 Phase 3 STX209 (arbaclofen)
44 Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) Completed NCT01825798 Phase 3 Metformin;Placebo
45 Psychotherapy for Anxiety in Children With Autism Spectrum Disorder Completed NCT02028247 Phase 3
46 Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders Completed NCT01302964 Phase 3 Placebo;Mirtazapine
47 Encopresis & MIE (DoD #2) Recruiting NCT03197922 Phase 3
48 Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder Recruiting NCT03715166 Phase 3 Bumetanide Oral Solution;Placebo
49 D-Cycloserine and Social Skills Training in Autism Spectrum Disorders Completed NCT01086475 Phase 3 D-cycloserine;Placebo
50 Folinic Acid in Autism Completed NCT03771560 Phase 2, Phase 3 folinic acid

Search NIH Clinical Center for Autism Spectrum Disorder

Cochrane evidence based reviews: autism spectrum disorder

Genetic Tests for Autism Spectrum Disorder

Genetic tests related to Autism Spectrum Disorder:

# Genetic test Affiliating Genes
1 Autism Spectrum Disorder 30 PTCHD1 RPL10 SHANK2

Anatomical Context for Autism Spectrum Disorder

MalaCards organs/tissues related to Autism Spectrum Disorder:

42
Brain, Testes, Eye, Bone, Cortex, Heart, Amygdala

Publications for Autism Spectrum Disorder

Articles related to Autism Spectrum Disorder:

(show top 50) (show all 5154)
# Title Authors Year
1
The role of alexithymia in parent-child interaction and in the emotional ability of children with autism spectrum disorder. ( 30624024 )
2019
2
Does Peer Rejection Moderate the Associations among Cyberbullying Victimization, Depression, and Anxiety among Adolescents with Autism Spectrum Disorder? ( 30836698 )
2019
3
Development of the Parent-Rated Anxiety Scale for Youth with Autism Spectrum Disorder. ( 30797036 )
2019
4
Effects of Cognitive Behavioral Therapy for Reducing Anxiety in Children with High Functioning ASD: A Systematic Review and Meta-Analysis. ( 30810842 )
2019
5
The Role of Sensory Features in Mediating Associations Between Autism Symptoms and Anxiety in Boys with Autism Spectrum Disorder. ( 30771129 )
2019
6
The neurobiological presentation of anxiety in autism spectrum disorder: A systematic review. ( 30629807 )
2019
7
A Retrospective Chart Review of Buspirone for the Treatment of Anxiety in Psychiatrically Referred Youth with High-Functioning Autism Spectrum Disorder. ( 30452283 )
2019
8
Open Trial of Modular Cognitive-Behavioral Therapy in the Treatment of Anxiety Among Late Adolescents with Autism Spectrum Disorder. ( 29855820 )
2019
9
Parental asthma and risk of autism spectrum disorder in offspring: a population and family based case-control study. ( 30742718 )
2019
10
Case report: Atrioventricular block after transcatheter atrial septal closure using the Figulla® Flex II ASD occluder. ( 30773790 )
2019
11
Distinct Methylphenidate-Evoked Response Measured Using Functional Near-Infrared Spectroscopy During Go/No-Go Task as a Supporting Differential Diagnostic Tool Between Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder Comorbid Children. ( 30800062 )
2019
12
Internet addiction and attention-deficit / hyperactivity disorder symptoms in adolescents with autism spectrum disorder. ( 30877993 )
2019
13
Corrigendum: Sensory Processing in Children with Autism Spectrum Disorder and/or Attention Deficit Hyperactivity Disorder in the Home and Classroom Contexts. ( 30890985 )
2019
14
ADGRL3 rs6551665 as a Common Vulnerability Factor Underlying Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder. ( 30652248 )
2019
15
Social functioning in youth with attention-deficit/hyperactivity disorder and autism spectrum disorder: transdiagnostic commonalities and differences. ( 30658861 )
2019
16
Structural neuroimaging correlates of social deficits are similar in autism spectrum disorder and attention-deficit/hyperactivity disorder: analysis from the POND Network. ( 30718456 )
2019
17
Sleep Problem Detection and Documentation in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder by Developmental-Behavioral Pediatricians: A DBPNet Study. ( 30589766 )
2019
18
Overlaps and distinctions between attention deficit/hyperactivity disorder and autism spectrum disorder in young adulthood: Systematic review and guiding framework for EEG-imaging research. ( 30367918 )
2019
19
A comparison of stimulus set size on tact training for children with autism spectrum disorder. ( 30883736 )
2019
20
Changing Conceptualizations of Regression: What Prospective Studies Reveal About the Onset of Autism Spectrum Disorder. ( 30885812 )
2019
21
Conceptualizing bullying in children with autism spectrum disorder: Using a mixed model to differentiate behavior types and identify predictors. ( 30887817 )
2019
22
Clinical Validation of the Autism Behavior Inventory: Caregiver-Rated Assessment of Core and Associated Symptoms of Autism Spectrum Disorder. ( 30888551 )
2019
23
Brief Report: Behavior Disorders and Social Skills in Adolescents with Autism Spectrum Disorder: Does IQ Matter? ( 30888552 )
2019
24
Non-speech and Speech Pitch Perception among Cantonese-speaking Children with Autism Spectrum Disorder: an ERP Study. ( 30890474 )
2019
25
Power spectrum of spontaneous cerebral homodynamic oscillation shows a distinct pattern in autism spectrum disorder. ( 30891353 )
2019
26
Do Children with Autism Spectrum Disorder Understand Their Academic Competencies? ( 30891664 )
2019
27
Birth seasonality and risk of autism spectrum disorder. ( 30891686 )
2019
28
Risk factors underlying depressive symptoms among parents/primary care providers of kids with autism spectrum disorder: A study from Muscat, Oman. ( 30891771 )
2019
29
Meeting the 24-hr movement guidelines: An update on US youth with autism spectrum disorder from the 2016 National Survey of Children's Health. ( 30892834 )
2019
30
Assessment of racial and ethnic bias in autism spectrum disorder prevalence estimates from a US surveillance system. ( 30892923 )
2019
31
Needs, strain, coping, and mental health among caregivers of individuals with autism spectrum disorder: A moderated mediation analysis. ( 30892929 )
2019
32
Prenatal and infant exposure to ambient pesticides and autism spectrum disorder in children: population based case-control study. ( 30894343 )
2019
33
Effects of Mindfulness-Based Positive Behavior Support (MBPBS) Training Are Equally Beneficial for Mothers and Their Children With Autism Spectrum Disorder or With Intellectual Disabilities. ( 30894823 )
2019
34
Assessing a Hyperarousal Hypothesis of Insomnia in Adults with Autism Spectrum Disorder. ( 30896090 )
2019
35
Effects of Dog Assisted Therapy for Adults with Autism Spectrum Disorder: An Exploratory Randomized Controlled Trial. ( 30900194 )
2019
36
Link-Level Functional Connectivity Neuroalterations in Autism Spectrum Disorder: A Developmental Resting-State fMRI Study. ( 30901848 )
2019
37
Editorial: Autism Spectrum Disorder and Autoimmune Diseases: A Pathway in Common? ( 30902666 )
2019
38
Parent Perspectives Towards Genetic and Epigenetic Testing for Autism Spectrum Disorder. ( 30903561 )
2019
39
Characterization of behavioral phenotypes in the BTBR T+ Itpr3tf/J mouse model of Autism Spectrum Disorder under social housing conditions using the Multiple Animal Positioning System. ( 30905912 )
2019
40
Improving Access to Diagnostic Assessments for Autism Spectrum Disorder Using an Arena Model. ( 30907770 )
2019
41
Disparities in Care: Do Children with Autism Spectrum Disorder Experience Differential Medication Receipt In The Emergency Department? ( 30907771 )
2019
42
Features of Catatonia in a 12-Year-Old Boy with Autism Spectrum Disorder. ( 30907773 )
2019
43
Effect of Wearable Digital Intervention for Improving Socialization in Children With Autism Spectrum Disorder: A Randomized Clinical Trial. ( 30907929 )
2019
44
Screen Media and Autism Spectrum Disorder: A Systematic Literature Review. ( 30908423 )
2019
45
Signs of enhanced formation of gist memory in children with autism spectrum disorder - a study of memory functions of sleep. ( 30908649 )
2019
46
SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons. ( 30911184 )
2019
47
Prevalence, Characteristics and Diabetes Management in Children with Comorbid Autism Spectrum Disorder and Type 1 Diabetes. ( 30912248 )
2019
48
Caregiver Daily Reporting of Symptoms in Autism Spectrum Disorder: Observational Study Using Web and Mobile Apps. ( 30912762 )
2019
49
Can I teach students with Autism Spectrum Disorder?: Investigating teacher self-efficacy with an emerging population of students. ( 30913505 )
2019
50
Electrophysiology of Inhibitory Control in the Context of Emotion Processing in Children With Autism Spectrum Disorder. ( 30914937 )
2019

Variations for Autism Spectrum Disorder

ClinVar genetic disease variations for Autism Spectrum Disorder:

6 (show top 50) (show all 783)
# Gene Variation Type Significance SNP ID Assembly Location
1 TPTE NM_199261.3(TPTE): c.1357-3_1357-2delTA deletion Uncertain significance rs149363218 GRCh37 Chromosome 21, 10910401: 10910402
2 TPTE NM_199261.3(TPTE): c.1357-3_1357-2delTA deletion Uncertain significance rs149363218 GRCh38 Chromosome 21, 10602055: 10602056
3 19p13.12 duplication duplication Likely pathogenic
4 MEF2C NM_002397.4(MEF2C): c.766C> T (p.Arg256Ter) single nucleotide variant Pathogenic rs796052733 GRCh38 Chromosome 5, 88731773: 88731773
5 MEF2C NM_002397.4(MEF2C): c.766C> T (p.Arg256Ter) single nucleotide variant Pathogenic rs796052733 GRCh37 Chromosome 5, 88027590: 88027590
6 TSC2 NM_000548.4(TSC2): c.1081C> G (p.Leu361Val) single nucleotide variant Likely pathogenic rs796053483 GRCh38 Chromosome 16, 2060775: 2060775
7 TSC2 NM_000548.4(TSC2): c.1081C> G (p.Leu361Val) single nucleotide variant Likely pathogenic rs796053483 GRCh37 Chromosome 16, 2110776: 2110776
8 SHANK3 NM_033517.1(SHANK3): c.3679dupG (p.Ala1227Glyfs) duplication Pathogenic rs762292772 GRCh37 Chromosome 22, 51159940: 51159940
9 SHANK3 NM_033517.1(SHANK3): c.3679dupG (p.Ala1227Glyfs) duplication Pathogenic rs762292772 GRCh38 Chromosome 22, 50721512: 50721512
10 ANKRD11 NM_001256182.1(ANKRD11): c.6323G> A (p.Gly2108Asp) single nucleotide variant Likely benign rs201509886 GRCh37 Chromosome 16, 89346627: 89346627
11 ANKRD11 NM_001256182.1(ANKRD11): c.6323G> A (p.Gly2108Asp) single nucleotide variant Likely benign rs201509886 GRCh38 Chromosome 16, 89280219: 89280219
12 RNF135 NM_032322.3(RNF135): c.1015delG (p.Val339Serfs) deletion Conflicting interpretations of pathogenicity rs724159978 GRCh37 Chromosome 17, 29325925: 29325925
13 RNF135 NM_032322.3(RNF135): c.1015delG (p.Val339Serfs) deletion Conflicting interpretations of pathogenicity rs724159978 GRCh38 Chromosome 17, 30998907: 30998907
14 NR3C2 NM_000901.4(NR3C2): c.1609C> T (p.Arg537Ter) single nucleotide variant Pathogenic rs121912562 GRCh37 Chromosome 4, 149356404: 149356404
15 NR3C2 NM_000901.4(NR3C2): c.1609C> T (p.Arg537Ter) single nucleotide variant Pathogenic rs121912562 GRCh38 Chromosome 4, 148435252: 148435252
16 MAP2K1 NM_002755.3(MAP2K1): c.199G> A (p.Asp67Asn) single nucleotide variant Pathogenic rs727504317 GRCh37 Chromosome 15, 66727483: 66727483
17 MAP2K1 NM_002755.3(MAP2K1): c.199G> A (p.Asp67Asn) single nucleotide variant Pathogenic rs727504317 GRCh38 Chromosome 15, 66435145: 66435145
18 TSC1 NM_000368.4(TSC1): c.1079C> A (p.Thr360Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs118203493 GRCh37 Chromosome 9, 135786451: 135786451
19 TSC1 NM_000368.4(TSC1): c.1079C> A (p.Thr360Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs118203493 GRCh38 Chromosome 9, 132911064: 132911064
20 TSC2 NM_000548.3(TSC2): c.4285G> T (p.Ala1429Ser) single nucleotide variant Benign/Likely benign rs45474795 GRCh37 Chromosome 16, 2134508: 2134508
21 TSC2 NM_000548.3(TSC2): c.4285G> T (p.Ala1429Ser) single nucleotide variant Benign/Likely benign rs45474795 GRCh38 Chromosome 16, 2084507: 2084507
22 TSC1 NM_000368.4(TSC1): c.1342C> T (p.Pro448Ser) single nucleotide variant Benign/Likely benign rs118203518 GRCh37 Chromosome 9, 135782214: 135782214
23 TSC1 NM_000368.4(TSC1): c.1342C> T (p.Pro448Ser) single nucleotide variant Benign/Likely benign rs118203518 GRCh38 Chromosome 9, 132906827: 132906827
24 TSC1 NM_000368.4(TSC1): c.346T> G (p.Leu116Val) single nucleotide variant Conflicting interpretations of pathogenicity rs199620268 GRCh37 Chromosome 9, 135800991: 135800991
25 TSC1 NM_000368.4(TSC1): c.346T> G (p.Leu116Val) single nucleotide variant Conflicting interpretations of pathogenicity rs199620268 GRCh38 Chromosome 9, 132925604: 132925604
26 TSC2 NM_000548.4(TSC2): c.2879C> T (p.Ser960Phe) single nucleotide variant not provided rs397514898 GRCh37 Chromosome 16, 2127640: 2127640
27 TSC2 NM_000548.4(TSC2): c.2879C> T (p.Ser960Phe) single nucleotide variant not provided rs397514898 GRCh38 Chromosome 16, 2077639: 2077639
28 TSC2 NM_000548.4(TSC2): c.2183G> T (p.Cys728Phe) single nucleotide variant Uncertain significance rs397514908 GRCh37 Chromosome 16, 2122327: 2122327
29 TSC2 NM_000548.4(TSC2): c.2183G> T (p.Cys728Phe) single nucleotide variant Uncertain significance rs397514908 GRCh38 Chromosome 16, 2072326: 2072326
30 TSC2 NM_000548.4(TSC2): c.1597A> C (p.Lys533Gln) single nucleotide variant not provided rs397515038 GRCh37 Chromosome 16, 2114426: 2114426
31 TSC2 NM_000548.4(TSC2): c.1597A> C (p.Lys533Gln) single nucleotide variant not provided rs397515038 GRCh38 Chromosome 16, 2064425: 2064425
32 TSC2 NM_000548.4(TSC2): c.2632C> T (p.Pro878Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs397515077 GRCh37 Chromosome 16, 2125886: 2125886
33 TSC2 NM_000548.4(TSC2): c.2632C> T (p.Pro878Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs397515077 GRCh38 Chromosome 16, 2075885: 2075885
34 TSC2 NM_000548.4(TSC2): c.190A> G (p.Ile64Val) single nucleotide variant Uncertain significance rs397515081 GRCh37 Chromosome 16, 2100452: 2100452
35 TSC2 NM_000548.4(TSC2): c.190A> G (p.Ile64Val) single nucleotide variant Uncertain significance rs397515081 GRCh38 Chromosome 16, 2050451: 2050451
36 TSC2 NM_000548.4(TSC2): c.5072T> C (p.Met1691Thr) single nucleotide variant Uncertain significance rs397515110 GRCh37 Chromosome 16, 2138052: 2138052
37 TSC2 NM_000548.4(TSC2): c.5072T> C (p.Met1691Thr) single nucleotide variant Uncertain significance rs397515110 GRCh38 Chromosome 16, 2088051: 2088051
38 TSC2 NM_000548.4(TSC2): c.2950G> C (p.Glu984Gln) single nucleotide variant not provided rs397515156 GRCh37 Chromosome 16, 2127711: 2127711
39 TSC2 NM_000548.4(TSC2): c.2950G> C (p.Glu984Gln) single nucleotide variant not provided rs397515156 GRCh38 Chromosome 16, 2077710: 2077710
40 TSC2 NM_000548.4(TSC2): c.5155G> A (p.Ala1719Thr) single nucleotide variant Uncertain significance rs201206500 GRCh37 Chromosome 16, 2138135: 2138135
41 TSC2 NM_000548.4(TSC2): c.5155G> A (p.Ala1719Thr) single nucleotide variant Uncertain significance rs201206500 GRCh38 Chromosome 16, 2088134: 2088134
42 TSC2 NM_000548.4(TSC2): c.2861A> G (p.Lys954Arg) single nucleotide variant not provided rs397515191 GRCh37 Chromosome 16, 2127622: 2127622
43 TSC2 NM_000548.4(TSC2): c.2861A> G (p.Lys954Arg) single nucleotide variant not provided rs397515191 GRCh38 Chromosome 16, 2077621: 2077621
44 TSC2 NM_000548.4(TSC2): c.3989C> T (p.Thr1330Met) single nucleotide variant Conflicting interpretations of pathogenicity rs397515209 GRCh37 Chromosome 16, 2133801: 2133801
45 TSC2 NM_000548.4(TSC2): c.3989C> T (p.Thr1330Met) single nucleotide variant Conflicting interpretations of pathogenicity rs397515209 GRCh38 Chromosome 16, 2083800: 2083800
46 TSC2 NM_000548.4(TSC2): c.454C> G (p.His152Asp) single nucleotide variant Uncertain significance rs397515285 GRCh37 Chromosome 16, 2104414: 2104414
47 TSC2 NM_000548.4(TSC2): c.454C> G (p.His152Asp) single nucleotide variant Uncertain significance rs397515285 GRCh38 Chromosome 16, 2054413: 2054413
48 POGZ NM_015100.3(POGZ): c.1426C> T (p.Arg476Trp) single nucleotide variant Uncertain significance rs267598016 GRCh37 Chromosome 1, 151396522: 151396522
49 POGZ NM_015100.3(POGZ): c.1426C> T (p.Arg476Trp) single nucleotide variant Uncertain significance rs267598016 GRCh38 Chromosome 1, 151424046: 151424046
50 POGZ NM_015100.3(POGZ): c.1426C> T (p.Arg476Trp) single nucleotide variant Uncertain significance rs267598016 NCBI36 Chromosome 1, 149663146: 149663146

Expression for Autism Spectrum Disorder

Search GEO for disease gene expression data for Autism Spectrum Disorder.

Pathways for Autism Spectrum Disorder

Pathways related to Autism Spectrum Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.58 MAP2K1 MIR106B MIR128-1 MIR15A MIR15B MIR181D
2 11.49 MAP2K1 MEF2C TSC2
3 10.71 MEF2C MIR128-1 MIR181D

GO Terms for Autism Spectrum Disorder

Cellular components related to Autism Spectrum Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.17 MIR106B MIR128-1 MIR132 MIR140 MIR15A MIR15B
2 ionotropic glutamate receptor complex GO:0008328 9.16 SHANK2 SHANK3
3 neuron spine GO:0044309 8.96 SHANK2 SHANK3

Biological processes related to Autism Spectrum Disorder according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.72 MIR106B MIR15A MIR15B
2 social behavior GO:0035176 9.65 PTCHD1 SHANK2 SHANK3
3 positive regulation of excitatory postsynaptic potential GO:2000463 9.59 SHANK2 SHANK3
4 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.58 MIR15A MIR15B
5 positive regulation of dendritic spine development GO:0060999 9.58 SHANK2 SHANK3
6 negative regulation of blood vessel endothelial cell migration GO:0043537 9.58 MEF2C MIR132 MIR15B
7 positive regulation of endothelial cell apoptotic process GO:2000353 9.57 MIR132 MIR15A
8 brain morphogenesis GO:0048854 9.56 SHANK2 SHANK3
9 gene silencing by miRNA GO:0035195 9.56 MIR106B MIR128-1 MIR132 MIR140 MIR15A MIR15B
10 dendritic spine morphogenesis GO:0060997 9.54 SHANK2 SHANK3
11 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.54 MEF2C MIR140 MIR15A
12 long-term synaptic depression GO:0060292 9.52 SHANK2 SHANK3
13 exploration behavior GO:0035640 9.51 SHANK2 SHANK3
14 negative regulation of vascular endothelial cell proliferation GO:1905563 9.5 MEF2C MIR132 MIR15B
15 vocalization behavior GO:0071625 9.49 SHANK2 SHANK3
16 synaptic growth at neuromuscular junction GO:0051124 9.46 SHANK2 SHANK3
17 postsynaptic density assembly GO:0097107 9.43 SHANK2 SHANK3
18 regulation of AMPA receptor activity GO:2000311 9.43 MEF2C SHANK2 SHANK3
19 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.33 MEF2C MIR140 MIR15A
20 miRNA mediated inhibition of translation GO:0035278 9.02 MIR106B MIR132 MIR15A MIR15B MIR181D

Molecular functions related to Autism Spectrum Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR106B MIR128-1 MIR132 MIR140 MIR15A MIR15B
2 receptor signaling complex scaffold activity GO:0030159 9.16 SHANK2 SHANK3
3 GKAP/Homer scaffold activity GO:0030160 8.96 SHANK2 SHANK3

Sources for Autism Spectrum Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....